Cover Image
市場調查報告書

主要已開發國家的氣喘治療藥的全球市場 2020年:僅管專利失效,重度氣喘的個體化治療方法仍帶動市場成長

Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations

出版商 GBI Research 商品編碼 329427
出版日期 內容資訊 英文 142 Pages
訂單完成後即時交付
價格
Back to Top
主要已開發國家的氣喘治療藥的全球市場 2020年:僅管專利失效,重度氣喘的個體化治療方法仍帶動市場成長 Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations
出版日期: 2015年02月28日 內容資訊: 英文 142 Pages
簡介

全球的氣喘罹患率高,大概3億人患病。一般預期這個數字將進一步增加,至2025年達到4億人。氣喘治療藥市場在先進8個國家中預計今後也將持續成長,從2013年的184億美元擴大到2020年的217億美元。

本報告提供氣喘相關概要與已上市產品、臨床實驗中產品趨勢、到2020年的市場發展預測、共同開發及授權等今後的策略相關考察,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 疾病的簡介
  • 流行病學
  • 病因
  • 病理學
  • 症狀
  • 診斷
  • 重度評估
  • 治療
  • 治療流程
  • 治療市場區隔

第3章 已上市產品

  • 概要
  • 氣喘的維持療法的ICS
  • 氣喘的維持療法的ICS/LABA的組合治療
  • 氣喘的維持療法的ICS/LABA治療的追加治療
  • 已上市產品的熱圖

第4章 氣喘開發平台

  • 概要
  • 各開發階段、分子類型、計劃類型開發平台分析
  • 各分子標的開發平台分析
  • 氣喘臨床實驗趨勢
    • 失敗率
    • 期間
    • 規模
    • 比較指標
  • 有潛力開發平台分子
  • 開發中產品的熱圖及競爭矩陣

第5章 到2020年的市場預測

  • 各地區市場
  • 全球市場
  • 北美
  • 歐洲主要5個國家
  • 日本
  • 氣喘市場促進要素與阻礙

第6章 策略性考察

  • 共同開發
  • 授權

第7章 附錄

圖表

目錄
Product Code: GBIHC357MR

Executive Summary

GBI Research, a leading business intelligence provider, has released its latest research report,"Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations".The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.

The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025.

Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest.

Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion.

Scope

The report covers and includes -

  • An introduction to asthma, including discussion of disease epidemiology, etiology pathophysiology, symptoms, diagnosis, and treatment, with clinical data for drugs featured in the current treatment algorithm discussed in detail
  • In-depth analysis of the current marketed products landscape, including product profiles of the main drugs used and heat maps that compare their safety and efficacy parameters
  • Comprehensive analysis of the asthma pipeline by phase of development, molecule type, and molecular target and novelty, and comparative analysis of the most promising late-stage pipeline drugs, as well as heat maps and a competitor matrix that compares safety and efficacy parameters
  • Additional in-depth analysis of the asthma clinical trials landscape, including trends in size, duration and failure rate
  • Forecast projections for the asthma market to 2020, including analysis of the global market and each of the eight major markets and incorporating projected, low, and high-variance scenarios based on treatment usage patterns and annual cost of therapy in each of the major markets
  • Discussion of the strategic consolidations landscape, including trends in co-development and licensing deals relevant to asthma drug products

Reasons to buy

  • The report will assist business development and enable marketing executives to strategize their product launches by allowing them to -
  • Gain a comprehensive understanding of asthma, including diagnosis, disease severity, and treatment algorithms
  • Understand the current asthma marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved
  • Identify trends, developments, and prominent molecule types and molecular targets within the asthma pipeline
  • Gain an appreciation of the clinical and commercial aspects of the most promising late-stage pipeline molecules and their potential competitive impact on the future market
  • Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration and failure rate, phase of development, molecule type, and molecular target
  • Observe projections for treatment usage patterns, annual therapy costs, and market growth in the eight major markets and understand reasons for variance in projected patterns of growth

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Epidemiology
  • 2.3. Etiology
  • 2.4. Pathophysiology
  • 2.5. Symptoms
  • 2.6. Diagnosis
  • 2.7. Assessment of Disease Severity
  • 2.8. Treatment
  • 2.9. Treatment Algorithm
  • 2.10. Treatment Segments
    • 2.10.1. ICS Monotherapy for the Maintenance Treatment of Asthma
    • 2.10.2. Singulair (montelukast sodium) as First-Line Maintenance Therapy
    • 2.10.3. ICS/LABA Combination Therapy
    • 2.10.4. Add-on Therapies

3. Marketed Products

  • 3.1. Overview
  • 3.2. ICS for the Maintenance Treatment of Asthma
    • 3.2.1. Arnuity (fluticasone furoate) - GSK
  • 3.3. ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma
    • 3.3.1. Advair (fluticasone propionate and salmeterol xinafoate) - GSK
    • 3.3.2. Symbicort (budesonide and formoterol fumarate) - AstraZeneca, Co-Promotion with Astellas Pharma
    • 3.3.3. Dulera (mometasone furoate and formoterol fumarate) - Merck
    • 3.3.4. Relvar/Breo (vilanterol trifenatate and fluticasone furoate) - GlaxoSmithKline/Theravance
  • 3.4. Add-on Therapy to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma
    • 3.4.1. Xolair (omalizumab) - Novartis and Genentech
    • 3.4.2. Singulair (montelukast) - Merck
    • 3.4.3. Spiriva (tiotropium bromide) - Boehringer Ingelheim
  • 3.5. Heat Maps for Marketed Products

4. Asthma Pipeline

  • 4.1. Overview
  • 4.2. Pipeline Analysis by Stage of Development, Molecule Type and Program Type
  • 4.3. Pipeline Analysis by Molecular Target
  • 4.4. Asthma Clinical Trial Landscape
    • 4.4.1. Clinical Trial Failure Rates
    • 4.4.2. Clinical Trial Duration
    • 4.4.3. Clinical Trial Size
    • 4.4.4. Comparative Clinical Trial Metrics Analysis
  • 4.5. Promising Pipeline Molecules
    • 4.5.1. Mepolizumab - GSK
    • 4.5.2. Reslizumab - Teva Pharmaceutical
    • 4.5.3. Lebrikizumab - Roche/Genentech
    • 4.5.4. Dupilumab - Regeneron Pharmaceuticals in Collaboration with Sanofi
    • 4.5.5. Masitinib - AB Science
  • 4.6. Heat Map and Competitor Matrix for Pipeline Products

5. Market Forecast to 2020

  • 5.1. Geographical Markets
  • 5.2. Global Market
  • 5.3. North America
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. Top Five Countries of Europe
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Japan
    • 5.5.1. Treatment Usage Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Size
  • 5.6. Drivers and Barriers for the Asthma Market
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Strategic Consolidations

  • 6.1. Co-development Deals
    • 6.1.1. Sepracor Enters into Co-Development Agreement with Nycomed for Ciclesonide
    • 6.1.2. NeoStem Enters into Agreement with University of California to Develop Human Regulatory T Cells
    • 6.1.3. Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies
  • 6.2. Licensing Deals
    • 6.2.1. Amgen Enters into Licensing Agreement with Kyowa Hakko Kirin - Terminated
    • 6.2.2. Mundipharma Enters into Licensing Agreement with SkyePharma
    • 6.2.3. MAP Pharmaceuticals Enters into Licensing Agreement with AstraZeneca - Terminated
    • 6.2.4. Orexo Enters into Licensing Agreement with Janssen Pharmaceuticals - Terminated
    • 6.2.5. Aslan Pharma Enters into Licensing Agreement with CSL for CSL-334

7. Appendix

  • 7.1. All Pipeline Drugs by Phase of Development
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. Phase I
    • 7.1.4. Phase II
    • 7.1.5. Phase III
    • 7.1.6. Pre-registration
  • 7.2. Market Forecasts to 2020
    • 7.2.1. Global
    • 7.2.2. US
    • 7.2.3. Canada
    • 7.2.4. UK
    • 7.2.5. France
    • 7.2.6. Germany
    • 7.2.7. Italy
    • 7.2.8. Spain
    • 7.2.9. Japan
  • 7.3. References
  • 7.4. Abbreviations
  • 7.5. Research Methodology
    • 7.5.1. Secondary Research
    • 7.5.2. Marketed Product Profiles
    • 7.5.3. Late-Stage Pipeline Candidates
    • 7.5.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 7.5.5. Product Competitiveness Framework
    • 7.5.6. Pipeline Analysis
    • 7.5.7. Forecasting Model
    • 7.5.8. Deals Data Analysis
  • 7.6. Expert Panel Validation
  • 7.7. Contact Us
  • 7.8. Disclaimer

List of Tables

  • Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 0-4 Years of Age
  • Table 2: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 5-11 Years of Age
  • Table 3: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Youths ≥ 12 Years of Age and Adults
  • Table 4: Management of Chronic Asthma
  • Table 5: Management of Acute Asthma
  • Table 6: Asthma Clinical Trial Endpoints
  • Table 7: Asthma Therapeutics, Global, All Pipeline Products, Discovery Phase, 2015
  • Table 8: Asthma Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2015
  • Table 9: Asthma Therapeutics, Global, All Pipeline Products, Phase I, 2015
  • Table 10: Asthma Therapeutics, Global, All Pipeline Products, Phase II, 2015
  • Table 11: Asthma Therapeutics, Global, All Pipeline Products, Phase III, 2015
  • Table 12: Asthma Therapeutics, Global, All Pipeline Products, Pre-registration Phase, 2015
  • Table 13: Asthma Therapeutics Market, Global, Market Forecast, 2013-2020
  • Table 14: Asthma Therapeutics Market, US, Market Forecast, 2013-2020
  • Table 15: Asthma Therapeutics Market, Canada, Market Forecast, 2013-2020
  • Table 16: Asthma Therapeutics Market, UK, Market Forecast, 2013-2020
  • Table 17: Asthma Therapeutics Market, France, Market Forecast, 2013-2020
  • Table 18: Asthma Therapeutics Market, Germany, Market Forecast, 2013-2020
  • Table 19: Asthma Therapeutics Market, Italy, Market Forecast, 2013-2020
  • Table 20: Asthma Therapeutics Market, Spain, Market Forecast, 2013-2020
  • Table 21: Asthma Therapeutics Market, Japan, Market Forecast, 2013-2020

List of Figures

  • Figure 1: Asthma Therapeutics Market, Global, Heat Map for Marketed Products, 2015
  • Figure 2: Asthma Therapeutics Market, Global, Heat Map for Marketed Products (continued), 2015
  • Figure 3: Asthma Therapeutics Market, Global, Pipeline, 2015
  • Figure 4: Asthma Therapeutics Market, Global, Pipeline by Molecular Target, 2015
  • Figure 5: Asthma Therapeutics Market, Global, Pipeline by Molecular Target, Breakdown of Immune/Inflammatory System Targets and Cytokine/Cytokine Receptor Targets, 2015
  • Figure 6: Asthma Therapeutics Market, Global, Pipeline by Molecular Target, Breakdown of Enzyme and Kinase Molecular Targets, 2015
  • Figure 7: Asthma Therapeutics Market, Global, Pipeline by Molecular Target, Breakdown of Adrenergic and Cholinergic Receptors, 2015
  • Figure 8: Asthma Therapeutics Market, Global, Clinical Trial Failure Rate, 2006-2014
  • Figure 9: Asthma Therapeutics Market, Global, Clinical Trial Failure Rate by Molecule Type, 2006-2014
  • Figure 10: Asthma Therapeutics Market, Global, Clinical Trial Failure Rate by Molecular Target, 2006-2014
  • Figure 11: Asthma Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type, (months), 2006-2014
  • Figure 12: Asthma Therapeutics Market, Global, Phase I Clinical Trial Duration by Molecular Target (months), 2006-2014
  • Figure 13: Asthma Therapeutics Market, Global, Phase II Clinical Trial Duration by Molecular Target (months), 2006-2014
  • Figure 14: Asthma Therapeutics Market, Global, Phase III Clinical Trial Duration by Molecular Target (months), 2006-2014
  • Figure 15: Asthma Therapeutics Market, Global, Clinical Trial Recruitment Size by Stage of Development and Molecule Type for Individual Asthma Products (participants), 2006-2014
  • Figure 16: Asthma Therapeutics Market, Global, Clinical Trial Recruitment Size by Stage of Development and Molecule Type for Individual Asthma Clinical Trials (participants), 2006-2014
  • Figure 17: Asthma Therapeutics Market, Global, Phase I Clinical Trial Recruitment Size by Molecular Target (participants), 2006-2014
  • Figure 18: Asthma Therapeutics Market, Global, Phase II Clinical Trial Recruitment Size by Molecular Target (participants), 2006-2014
  • Figure 19: Asthma Therapeutics Market, Global, Phase III Clinical Trial Recruitment Size by Molecular Target (participants), 2006-2014
  • Figure 20: Asthma Therapeutics Market, Global, Failure Rate (%), Average Clinical Trial Duration (months) and Average Recruitment Size for Asthma by Molecule Type, 2006-2014
  • Figure 21: Asthma Therapeutics Market, Global Failure Rate (%), Average Clinical Trial Duration (months) and Average Trial Recruitment Size (participants) for Asthma by Molecular Target, 2006-2014
  • Figure 22: Asthma Therapeutics Market, Global, Mepolizumab Forecast ($bn), 2015-2020
  • Figure 23: Asthma Therapeutics Market, Global, Reslizumab Forecast ($bn), 2016-2020
  • Figure 24: Asthma Therapeutics Market, Global, Lebrikizumab Forecast ($m), 2018-2020
  • Figure 25: Asthma Therapeutics Market, Global, Dupilumab Forecast ($m), 2018-2020
  • Figure 26: Asthma Therapeutics Market, Global, Masitinib Forecast ($m), 2017-2020
  • Figure 27: Asthma Therapeutics Market, Global, Heat Map for Pipeline Products, 2015
  • Figure 28: Asthma Therapeutics Market, Global, Competitor Matrix for Marketed and Pipeline Products, 2015
  • Figure 29: Asthma Therapeutics Market, Global, Treatment Patterns, 2013-2020
  • Figure 30: Asthma Therapeutics Market, Global, Market Size ($bn), 2013-2020
  • Figure 31: Asthma Therapeutics Market, North America, Treatment Patterns, 2013-2020
  • Figure 32: Asthma Therapeutics Market, North America, Annual Cost of Therapy ($), 2013-2020
  • Figure 33: Asthma Therapeutics Market, North America, Market Size, 2013-2020
  • Figure 34: Asthma Therapeutics Market, Top Five EU Countries, Treatment Patterns, 2013-2020
  • Figure 35: Asthma Therapeutics Market, Top Five EU Countries, Annual Cost of Therapy ($), 2013-2020
  • Figure 36: Asthma Therapeutics Market, Top Five EU Countries, Market Size, 2013-2020
  • Figure 37: Asthma Therapeutics Market, Japan, Treatment Patterns, 2013-2020
  • Figure 38: Asthma Therapeutics Market, Japan, Annual Cost of Therapy ($), 2013-2020
  • Figure 39: Asthma Therapeutics Market, Japan, Market Size ($bn), 2013-2020
  • Figure 40: Asthma Therapeutics Market, Global, Co-Development Deals by Region, 2006-2014
  • Figure 41: Asthma Therapeutics Market, Global, Co-Development Deals by Value ($m), 2006-2014
  • Figure 42: Asthma Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-Development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2014
  • Figure 43: Asthma Therapeutics Market, Global, Co-Development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2014
  • Figure 44: Asthma Therapeutics Market, Global, Co-Development Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2014
  • Figure 45: Asthma Therapeutics Market, Global, Co-Development Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2014
  • Figure 46: Asthma Therapeutics Market, Global, Licensing Deals by Region, 2006-2014
  • Figure 47: Asthma Therapeutics Market, Global, Licensing Deals by Value ($m), 2006-2014
  • Figure 48: Asthma Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2014
  • Figure 49: Asthma Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2014
  • Figure 50: Asthma Therapeutics Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2014
  • Figure 51: Asthma Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2014
Back to Top